Search
Novabridge Biosciences ADR
NBPAdd to Watchlist
1.820USD
-0.100-5.21%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
210.48MMarket Cap
LossP/E TTM
More Details of Company
Novabridge Biosciences ADR Info
Ticker Symbol- -
Company name- -
IPO date- -
CEO- -
Number of employees- -
Security type- -
Fiscal year-end- -
Address- -
City- -
Stock exchange- -
Country- -
Postal code- -
Phone- -
Website- -
Ticker Symbol- -
IPO date- -
CEO- -
Company Executives of Novabridge Biosciences ADR
Name
Name/Position
Position
Shareholding
Change
Mr. Wei Fu
Mr. Wei Fu
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Chun Kwok (Alan) Au
Mr. Chun Kwok (Alan) Au
Independent Director
Independent Director
--
--
Mr. Chia-Hung (Conor) Yang
Mr. Chia-Hung (Conor) Yang
Independent Director
Independent Director
--
--
Dr. Phillip Dennis, M.D., Ph.D.
Dr. Phillip Dennis, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Xi-Yong (Sean) Fu, Ph.D.
Dr. Xi-Yong (Sean) Fu, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Robert Lenz, M.D., Ph.D.
Dr. Robert Lenz, M.D., Ph.D.
Independent Director
Independent Director
--
--
,
,
Independent Director
Independent Director
--
--
,
,
Chief Business Development Officer, Director
Chief Business Development Officer, Director
--
--
Mr. Kyler Lei
Mr. Kyler Lei
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Claire Xu
Mr. Claire Xu
Senior Vice President - Clinical Development
Senior Vice President - Clinical Development
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Wei Fu
Mr. Wei Fu
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Chun Kwok (Alan) Au
Mr. Chun Kwok (Alan) Au
Independent Director
Independent Director
--
--
Mr. Chia-Hung (Conor) Yang
Mr. Chia-Hung (Conor) Yang
Independent Director
Independent Director
--
--
Dr. Phillip Dennis, M.D., Ph.D.
Dr. Phillip Dennis, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Xi-Yong (Sean) Fu, Ph.D.
Dr. Xi-Yong (Sean) Fu, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Robert Lenz, M.D., Ph.D.
Dr. Robert Lenz, M.D., Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
China (Mainland)
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Wed, Apr 29
Updated: Wed, Apr 29
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Everest Medicines Ltd
13.70%
CBC Group
11.45%
Janus Henderson Investors
7.30%
T Investment Ltd
7.07%
HHLR Advisors, Ltd.
5.17%
Other
55.32%
Shareholders
Shareholders
Proportion
Everest Medicines Ltd
13.70%
CBC Group
11.45%
Janus Henderson Investors
7.30%
T Investment Ltd
7.07%
HHLR Advisors, Ltd.
5.17%
Other
55.32%
Shareholder Types
Shareholders
Proportion
Corporation
20.77%
Investment Advisor/Hedge Fund
14.37%
Private Equity
11.45%
Hedge Fund
7.48%
Investment Advisor
6.37%
Research Firm
3.54%
Individual Investor
0.56%
Venture Capital
0.31%
Other
35.15%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q4
71
44.19M
22.87%
--
2026Q1
119
50.63M
43.89%
-381.11K
2025Q4
112
44.52M
38.63%
+8.34M
2025Q3
118
43.87M
38.07%
+959.09K
2025Q2
118
26.13M
31.79%
-13.78M
2025Q1
122
24.15M
29.39%
-18.93M
2024Q4
134
22.41M
27.40%
-20.19M
2024Q3
146
29.96M
36.94%
-20.28M
2024Q2
191
30.91M
38.11%
-23.68M
2024Q1
262
28.58M
35.04%
-19.41M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Everest Medicines Ltd
15.85M
13.74%
+15.85M
--
Aug 05, 2025
CBC Group
13.24M
11.48%
+1.29M
+10.76%
Jan 29, 2026
Janus Henderson Investors
8.44M
7.32%
+445.26K
+5.57%
Dec 31, 2025
T Investment Ltd
8.17M
7.09%
--
--
Mar 19, 2025
HHLR Advisors, Ltd.
5.98M
5.19%
--
--
Dec 31, 2025
Morgan Stanley & Co. LLC
3.61M
3.14%
+2.25M
+165.50%
Dec 31, 2025
Invus Public Equities Advisors, LLC
3.00M
2.6%
+1.83M
+157.30%
Dec 31, 2025
Point72 Asset Management, L.P.
2.30M
1.99%
+2.22M
+2871.64%
Dec 31, 2025
Candriam Luxembourg S.A.
1.62M
1.41%
+7.14K
+0.44%
Jan 31, 2026
View more
Related ETFs
Updated: Tue, Dec 9
Updated: Tue, Dec 9
Name
Proportion
ALPS Barron's 400 ETF
0.23%
SPDR S&P Emerging Markets Small Cap ETF
0.03%
SPDR S&P China ETF
0.01%
SPDR Portfolio Emerging Markets ETF
0.01%
ActivePassive International Equity ETF
0%
Avantis Emerging Markets Small Cap Equity ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
Invesco Golden Dragon China ETF
0%
SPDR S&P Emerging Asia Pacific ETF
0%
ALPS Barron's 400 ETF
Proportion0.23%
SPDR S&P Emerging Markets Small Cap ETF
Proportion0.03%
SPDR S&P China ETF
Proportion0.01%
SPDR Portfolio Emerging Markets ETF
Proportion0.01%
ActivePassive International Equity ETF
Proportion0%
Avantis Emerging Markets Small Cap Equity ETF
Proportion0%
Invesco NASDAQ Future Gen 200 ETF
Proportion0%
Invesco Golden Dragon China ETF
Proportion0%
SPDR S&P Emerging Asia Pacific ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
